Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Colorado for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Colorado only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Colorado (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Robert Rifkin (NPI 1134103476)

Field	Value
Entity Type	Individual
Organization	Robert Rifkin
Address	1800 N Williams St Ste 200
City	Denver
State	CO
ZIP	80218
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	November 30, 2005

Payer Source	Total Paid
Medicare	$3.3M
Medicaid	$0

Key Findings

ROBERT RIFKIN is a Hematology & Oncology physician in DENVER with lifetime Medicare revenue of $3.3M and no Medicaid billing on file; his NPI was enumerated on 2005-11-30 (~21 years ago), indicating long-established participation in Medicare and a practice profile concentrated on older adults. The absence of Medicaid activity makes this effectively a single-payer (Medicare) billing footprint for public programs.

Revenue concentration is high: the precomputed top 3 Medicare codes by revenue account for 68.4% of this provider's total Medicare revenue. Those top lines are A9607 ($1M, 32.2%), J9271 ($782.6K, 24.2%), and J9144 ($389.9K, 12.0%), showing a small number of therapies dominate receipts.

The top codes point to a specialized oncology infusion practice: A9607 is lutetium lu 177 vipivotide tetraxetan (radioligand therapy), J9271 is pembrolizumab (checkpoint inhibitor immunotherapy), and J9144 is daratumumab with hyaluronidase (a hematologic monoclonal antibody). This mix implies integrated infusion/radiopharmacy capability and focus on advanced systemic and radiopharmaceutical cancer treatments rather than primary-care services.

Competitive standing for the largest revenue drivers is mixed: A9607 ranks #31 of 44 providers nationally (30th percentile), indicating modest national presence for radioligand therapy; J9271 ranks #493 of 1841 (73th percentile) and J9144 ranks #205 of 615 (66th percentile), both characterized as typical, unremarkable volumes relative to national peers and consistent with a competent regional infusion provider rather than a national center of volume.

Office evaluation-and-management activity is unusually high: 99214 appears as an extreme outlier, with 1.3K claims generating $127.8K (3.9% of Medicare revenue) and ranking #5090 of 479517 providers nationally (99th percentile). This far-above-typical E/M volume suggests either a large established patient panel, frequent follow-up visits for active oncology care, or billing intensity concentrated in higher-level office visits.

Ancillary diagnostics and support services are material to the practice’s workflow: PET/CT 78815 contributes $205.8K (6.4%) and ranks #1225 of 6566 providers (81th percentile), while diagnostic A9595 contributes $134.8K (4.2%). In addition, a range of high-claim laboratory codes (e.g., 80053, 85025, 83615) appear with high national percentiles, consistent with on-site or regularly directed imaging and lab testing to support treatment and monitoring.

Drug-administration and infusion throughput is substantial: J9271 has 18.2K claims, J9144 10.3K claims, and supportive administration/infusion codes such as 96413 (385 claims) and 96367 (397 claims) are present. This pattern signals significant operational capacity for recurring infusions and the logistics of handling high-volume biologic and specialty drug regimens.

Payer-mix and business risk considerations follow directly from the data: with $3.3M in Medicare revenue and no Medicaid billing on file, the provider’s publicly billed revenue is heavily Medicare-dependent, concentrating exposure to Medicare reimbursement policy and care patterns typical of an older oncology population rather than a mixed Medicaid/non-Medicare case mix. That concentration should be factored into network contracting or risk-adjustment discussions.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

77 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
A9607	Lutetium lu 177 vipivotide tetraxetan, therapeutic, 1 millicurie	5,370	$190	$1M
J9271	Injection, pembrolizumab, 1 mg	18,200	$40	$782.6K
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	10,260	$40	$389.9K
78815	PET and CT scans are both standard imaging tools that allow doctors to evaluate the location and metabolic actions of tumors or cancer inside the body before beginning an active treatment regimen.…	170	$1,230	$205.8K
J1568	Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg	4,830	$30	$164.1K
A9595	Piflufolastat f-18, diagnostic, 1 millicurie	280	$490	$134.8K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	1,350	$100	$127.8K
J1930	Injection, lanreotide, 1 mg	2,610	$40	$112.2K
J0897	Injection, denosumab, 1 mg	3,780	$20	$68K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	390	$100	$40K

Showing 1–10 of 77

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 77 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Colorado Distribution

Robert Rifkin — 3 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Colorado

Full comparison — all codes billed, vs. state median

77 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
A9607	1	10	5,170	$190	$1M
J9271	5	40	10,700	$40	$520.5K
J9144	4	20	7,560	$40	$354.8K
J1930	4	10	5,420	$40	$253.1K
A9595	6	20	220	$540	$141.1K
J1568	5	30	2,240	$30	$101.5K
J0897	53	140	2,580	$20	$68.8K
78815	20	120	60	$540	$58.9K
Q5122	5	10	320	$90	$30.7K
J3490	6	60	50	$290	$23.1K

Showing 1–10 of 77

Related Providers

Other providers that share a Tax Identification Number (TIN) with Robert Rifkin, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Nauman Moazzam	CO	Hematology & Oncology Physician	$3.6M	$0
Ioana Hinshaw	CO	Hematology & Oncology Physician	$2.7M	$0
John Burke	CO	Hematology & Oncology Physician	$2.6M	$0
Cary Chisholm	TX	Anatomic Pathology & Clinical Pathology Physician	$2.5M	$24.7K
Patrick Eulitt	CO	Medical Oncology Physician	$2.4M	$0
Patrick Richard	CO	Radiation Oncology Physician	$1.9M	$0
Christopher Benton	CO	Hematology & Oncology Physician	$1.8M	$0
Paul Decarolis	CO	Hematology & Oncology Physician	$1.6M	$0
Joseph Dai	AL	Dermatology Physician	$1.6M	$0
Maurice Markus	CO	Hematology & Oncology Physician	$1.6M	$0

Nearby Providers

Other providers in the same ZIP code as Robert Rifkin, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Hca Healthone LLC	CO	General Acute Care Hospital	$0	$13.3M
Saint Joseph Hospital, Inc	CO	General Acute Care Hospital	$0	$12M
P2p Recovery Resources	CO	Substance Use Disorder Rehabilitation Clinic/Center	$0	$8.6M
Obstetrix Medical Group Of Colorado P C	CO	Neonatal-Perinatal Medicine Physician	$0	$7.8M
Eric S Yaeger Md PC	CO	Hospitalist Physician	$0	$3.7M
Sj East Campus Asc, LLC	CO	Ambulatory Surgical Clinic/Center	$1.1M	$0
Michele Basche	CO	Hematology & Oncology Physician	$854K	$0
Allen Cohn	CO	Hematology & Oncology Physician	$610.9K	$0
Richard Nash	CO	Hematology & Oncology Physician	$504.1K	$0
Michelle Levy	CO	Hematology & Oncology Physician	$497.8K	$0

Robert Rifkin — Billing Profile & Reimbursement Data

Sign up for Robert Rifkin — Billing Profile & Reimbursement Data policy alerts

Robert Rifkin — Billing Profile & Reimbursement Data

Sign up for Robert Rifkin — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References